BDR Pharma unveils generic cancer drug Cabozantinib in India
New Delhi: Drug firm BDR Pharmaceuticals on Tuesday said it has launched generic Cabozantinib, used for the treatment of various types of cancer, and will bring the product in India in the next few days.
Cabozantinib is used for the treatment of metastatic medullary thyroid cancer, advanced renal cell carcinoma and hepatocellular carcinoma, BDR Pharma said in a statement.
"Ensuring that all our patients have access to quality-produced, world-class treatment at a reasonable rate was the main reason for launching the drug in India," BDR Pharmaceuticals, Business Development - Director, Raheel Shah said.
The company, however, did not give any details about the cost of the drug.
Cabozantinib is prescribed for treating patients with progressive, metastatic medullary thyroid cancer and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma, BDR Pharma said.
The drug is available in the strengths of 20 mg, 40 mg and 60 mg, it added.
Another cancer drug was launched by the company earlier this year. Medical Dialogues Team had earlier reported that BDR Pharmaceutical had launched the BDPARIB (RUCAPARIB) to treat advanced ovarian and prostate cancers in the month of May 2021.
BDPARIB is the first affordable generic in India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the market.
Rucaparib is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2, and 3 used as a monotherapy and in conjunction with other anti-cancer agents in several tumor forms, including ovarian and prostate cancers. It has played a significant role in treating ovarian cancer patients with BRCA mutation (germline or somatic) associated with epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapy.